Evidence map›Paper›PMID 40009285›Full record

ArticleDiscover oncology2025

Genomic and micro-environmental insights into drug resistance in colorectal cancer liver metastases.

Junjie Kuang, Jun Li, Siwei Zhou, Yi Li, Jinbo Lin, Weizhen Huang, Xia Yuan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Junjie KuangThe Second Department of Oncology, Cancer Center, Huizhou First Hospital, Huizhou, Guangdong, China.
Jun LiThe Second Department of Oncology, Cancer Center, Huizhou First Hospital, Huizhou, Guangdong, China.
Siwei ZhouThe Second Department of Oncology, Cancer Center, Huizhou First Hospital, Huizhou, Guangdong, China.
Yi LiThe Second Department of Oncology, Cancer Center, Huizhou First Hospital, Huizhou, Guangdong, China.
Jinbo LinThe Second Department of Oncology, Cancer Center, Huizhou First Hospital, Huizhou, Guangdong, China.
Weizhen HuangThe Second Department of Oncology, Cancer Center, Huizhou First Hospital, Huizhou, Guangdong, China. flyzhen2008@163.com.
Xia YuanThe Second Department of Oncology, Cancer Center, Huizhou First Hospital, Huizhou, Guangdong, China. yuanxia71@hotmail.com.

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2022A1515011302Basic and Applied Basic Research Foundation of Guangdong Province 2023A1515140039
6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) is known for its high heterogeneity, with liver metastases significantly impairing survival outcomes. Understanding the tumor microenvironment (TME) and genomic alterations in metastatic sites is crucial for developing personalized therapies that overcome drug resistance and improve prognosis.

methodsWe profiled 54 CRC liver metastases, comparing them with 198 other metastatic lesions and normal liver tissues. By analyzing immune cell infiltration, stromal interactions, and key genomic alterations, we constructed an 11-gene prognostic model to predict survival and immunotherapy outcomes.

resultsCRC liver metastases with high-risk profiles demonstrated enriched follicular helper T cells, activated dendritic cells, and M2 macrophages in the TME. Frequent mutations in APC, TP53, KRAS, and PIK3CA were identified, alongside altered EGFR signaling. The 11-gene model effectively stratified patients by prognosis and predicted immunotherapy responses, emphasizing the therapeutic potential of targeting resistance mechanisms.

conclusionsThis study reveals how genomic and TME-driven factors contribute to drug resistance in CRC liver metastases. Integrating these insights with clinical data could advance precision therapies, addressing the evolving challenge of tumor drug resistance in CRC.

Indexed as

Colorectal cancerDrug resistanceGenomic alterationsImmune therapy responseLiver metastasisTumor microenvironment

Identifiers

PMID40009285
PMCPMC11865409

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.